changes result in slightly altered antibodies that may attach more strongly to a disease protein. The interaction between the antibody and the disease protein blocks the protein from doing harm in the body, effectively short-cutting a disease process.
Georgiou, who holds the Cockrell Family Regents Chair in Engineering #9, and Chemistry and Biochemistry Professor Brent Iverson, the Warren J. and Viola Mae Raymer Professor and Distinguished Teaching Professor, previously used the antibody evolution process to engineer a similar antibody that is in late-stage, clinical trials to treat human anthrax infections. Iverson is a co-author and a collaborator on the latest research.
To test the bacterium-only system, lead author Yariv Mazor, a postdoctoral student in chemical engineering, engineered antibodies to an anthrax toxin called PA. He and Thomas Van Blarcom, a graduate student in chemical engineering, used a method called APEx, co-developed by Georgiou and Iverson's lab, to identify the bacteria-bound antibodies that attach best to the PA. Van Blarcom then took those bacteria and grew large numbers of them to begin refining the steps needed for mass-scale production of promising therapeutic antibodies.
'"/>Source:
University of Texas at Austin
Page: 1 2 Related biology news :1.
Chemists create Superbowl molecule; May lead to better health2.
Protein discovery could unlock the secret to better TB treatment3.
Signaling protein builds bigger, better bones in mice4.
Harnessing microbes, one by one, to build a better nanoworld5.
Two are better than one6.
Discovery may lead to better Candidiasis drug7.
Insects, viruses could hold key for better human teamwork in disasters8.
Atmosphere may cleanse itself better than previously thought9.
Could better mangrove habitats have spared lives in the 2004 tsunami?10.
Muscle repair: Making a good system better, faster; implications for aging, disease11.
Plant genes identified that can form basis for crops better adapted to environmental conditions